Loading clinical trials...
Loading clinical trials...
A Multicenter, Prospective, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of ANG-3777 to Assess the Safety and Efficacy of BB3 in Patients Developing Acute Kidney Injury After Cardiac Surgery
Conditions
Interventions
ANG-3777
Placebo
Locations
40
United States
University of Southern California
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Stanford University Medical Center
Palo Alto, California, United States
California Institute of Renal Reseach
San Diego, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Fleming Island Center for Clinical Research
Fleming Island, Florida, United States
Start Date
February 24, 2017
Primary Completion Date
August 1, 2021
Completion Date
August 1, 2021
Last Updated
July 15, 2021
NCT06446739
NCT07490808
NCT05806645
NCT06337838
NCT06517810
NCT05318196
Lead Sponsor
Angion Biomedica Corp
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions